JP2017519807A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519807A5 JP2017519807A5 JP2017501186A JP2017501186A JP2017519807A5 JP 2017519807 A5 JP2017519807 A5 JP 2017519807A5 JP 2017501186 A JP2017501186 A JP 2017501186A JP 2017501186 A JP2017501186 A JP 2017501186A JP 2017519807 A5 JP2017519807 A5 JP 2017519807A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- dose
- patient
- disease
- blood concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 18
- 239000008280 blood Substances 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 9
- 230000016396 cytokine production Effects 0.000 claims description 9
- 201000001119 neuropathy Diseases 0.000 claims description 8
- 230000007823 neuropathy Effects 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 6
- 238000011084 recovery Methods 0.000 claims description 5
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 4
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 4
- 201000002832 Lewy body dementia Diseases 0.000 claims description 4
- 230000007658 neurological function Effects 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 230000036765 blood level Effects 0.000 claims description 3
- 230000001149 cognitive effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 2
- 206010033892 Paraplegia Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000032930 Spastic paraplegia Diseases 0.000 claims description 2
- 208000034799 Tauopathies Diseases 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 230000006870 function Effects 0.000 claims description 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 2
- 230000001314 paroxysmal effect Effects 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229940126560 MAPK inhibitor Drugs 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462022586P | 2014-07-09 | 2014-07-09 | |
| US62/022,586 | 2014-07-09 | ||
| PCT/US2015/039539 WO2016007616A1 (en) | 2014-07-09 | 2015-07-08 | Methods for treating neurologic disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519807A JP2017519807A (ja) | 2017-07-20 |
| JP2017519807A5 true JP2017519807A5 (enExample) | 2018-08-16 |
| JP6660369B2 JP6660369B2 (ja) | 2020-03-11 |
Family
ID=55064826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017501186A Active JP6660369B2 (ja) | 2014-07-09 | 2015-07-08 | 神経障害を治療する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9579322B2 (enExample) |
| EP (1) | EP3166610B1 (enExample) |
| JP (1) | JP6660369B2 (enExample) |
| CN (3) | CN106659723A (enExample) |
| WO (1) | WO2016007616A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3166610B1 (en) | 2014-07-09 | 2022-11-02 | Eip Pharma, LLC | Methods for treating neurologic disorders |
| WO2017075013A1 (en) * | 2015-10-26 | 2017-05-04 | Eip Pharma, Llc | Methods and compositions for recovery from stroke |
| WO2017185073A1 (en) * | 2016-04-21 | 2017-10-26 | Eip Pharma, Llc | Compositions and methods for treating dementia |
| US11466008B2 (en) | 2017-09-18 | 2022-10-11 | Eip Pharma, Llc | Co-crystals of neflamapimod (VX-745) |
| BR112020006677A2 (pt) | 2017-10-05 | 2020-10-06 | Fulcrum Therapeutics, Inc. | uso de inibidores p38 para reduzir a expressão de dux4 |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| WO2019178153A1 (en) * | 2018-03-12 | 2019-09-19 | Eip Pharma, Llc | Pharmaceutical formulations of neflamapimod |
| AU2019384074B2 (en) * | 2018-11-20 | 2025-04-10 | Sparrow Pharmaceuticals, Inc. | Methods for administering corticosteroids |
| EP3986396A4 (en) * | 2019-06-18 | 2023-08-02 | Opiant Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS OF TREATING ACUTE CANNABINOID OVERDOSAGE WITH A CANNABINOID RECEPTOR ANTAGONIST |
| WO2020257336A1 (en) | 2019-06-18 | 2020-12-24 | Opiant Pharmaceuticals, Inc. | Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist |
| JP7691971B2 (ja) * | 2019-07-12 | 2025-06-12 | イーアイピー ファーマ， インコーポレイテッド | レビー小体型認知症を処置するための組成物および方法 |
| EP4240486A4 (en) * | 2020-11-06 | 2024-05-22 | EIP Pharma, Inc. | TREATMENT OF GALKING DYSFUNCTION IN THE CONTEXT OF A NEURODEGENERATIVE DISEASE |
| CN113616795B (zh) * | 2021-08-31 | 2023-06-20 | 上海交通大学医学院附属瑞金医院 | Pp2a激动剂防治由正常衰老或pp2a活性或表达降低所导致的精神障碍 |
| JP2024541901A (ja) * | 2021-11-05 | 2024-11-13 | イーアイピー ファーマ， エルエルシー | レビー小体型認知症を有する患者の選択的集団の処置 |
| AU2024263955A1 (en) * | 2023-04-27 | 2025-11-20 | Remepy Health Ltd | Digital therapeutics |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6147080A (en) | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| CN1753662A (zh) * | 2002-12-24 | 2006-03-29 | 神经化学（国际）有限公司 | 用于治疗β－淀粉状蛋白相关疾病的治疗制剂 |
| AU2005227192A1 (en) | 2004-03-11 | 2005-10-06 | Kythera Biopharmaceuticals, Inc. | Compositions and methods for preventing and treating skin and hair conditions |
| US20050203111A1 (en) | 2004-03-12 | 2005-09-15 | Vvii Newco 2003, Inc. | Compositions and methods for preventing and treating skin and hair conditions |
| JP2009514851A (ja) | 2005-11-08 | 2009-04-09 | ランバクシー ラボラトリーズ リミテッド | （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法 |
| US20110201686A1 (en) | 2006-06-23 | 2011-08-18 | Yousef Al-Abed | Inhibitors of ASS and Synuclein Aggregation |
| CN102099036B (zh) * | 2008-06-03 | 2015-05-27 | 英特芒尼公司 | 用于治疗炎性疾患和纤维化疾患的化合物和方法 |
| WO2013043232A2 (en) * | 2011-04-08 | 2013-03-28 | Afraxis, Inc. | 8-ethyl-6-(aryl)pyrido [2,3-d]pyrimidin-7(8h) -ones for the treatment of nervous system disorders and cancer |
| DK3081568T3 (da) * | 2011-05-09 | 2020-02-24 | Eip Pharma Llc | Sammensætninger og fremgangsmåder til behandling af alzheimers sygdom |
| EP3166610B1 (en) | 2014-07-09 | 2022-11-02 | Eip Pharma, LLC | Methods for treating neurologic disorders |
-
2015
- 2015-07-08 EP EP15819113.0A patent/EP3166610B1/en active Active
- 2015-07-08 JP JP2017501186A patent/JP6660369B2/ja active Active
- 2015-07-08 CN CN201580037336.8A patent/CN106659723A/zh active Pending
- 2015-07-08 CN CN202110348688.2A patent/CN113018300B/zh active Active
- 2015-07-08 WO PCT/US2015/039539 patent/WO2016007616A1/en not_active Ceased
- 2015-07-08 US US14/794,469 patent/US9579322B2/en active Active
- 2015-07-08 CN CN202110783304.XA patent/CN114010641A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519807A5 (enExample) | ||
| Rivera-Oliver et al. | Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review | |
| Katzav et al. | Anti-P ribosomal antibodies induce defect in smell capability in a model of CNS-SLE (depression) | |
| JP2016199576A5 (enExample) | ||
| NO20091888L (no) | Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav | |
| FI3801536T3 (fi) | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| EA201991147A1 (ru) | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC | |
| EA201992178A1 (ru) | Фармацевтические композиции с высоким содержанием лекарственного средства из среднецепочечных триглицеридов и способы, связанные c ними | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| Khatoon et al. | The role of natural products in Alzheimer's and Parkinson's disease | |
| BR0314713A (pt) | Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias | |
| WO2007054348A1 (de) | Neue arzneimittel | |
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| Sartorius et al. | Medial Forebrain Bundle Stimulation—Speed Access to an Old or Entry into a New Depression Neurocircuit? | |
| CN105832724B (zh) | 吲哚醇在制备抗抑郁症药物中的用途 | |
| JP7062804B2 (ja) | レビー小体病の治療および／または予防剤 | |
| RU2325146C1 (ru) | Способ реабилитации больных рассеянным склерозом с нарушениями двигательных функций | |
| Nomoto et al. | Clinical nonmotor aspect of A2A antagonist in PD treatment | |
| Faraz et al. | Effect of Hypothyroidism on Motor Nerve Conduction Studies: A Cross Sectional Study | |
| TWI723012B (zh) | 額葉功能障礙之治療劑 | |
| JP2015137243A (ja) | 脳内アミノ酸量の調整剤 | |
| MX2019013717A (es) | Plasma de origen animal o fracciones del mismo para usarse en el tratamiento contra trastornos del deterioro cognitivo en humanos y animales de compañia. | |
| Mohanan et al. | Attenuating effect of cilostazol against vincristine–induced neuropathic pain in mice |